000893884 001__ 893884
000893884 005__ 20211018113109.0
000893884 0247_ $$2doi$$a10.1111/bjh.17479
000893884 0247_ $$2ISSN$$a0007-1048
000893884 0247_ $$2ISSN$$a1365-2141
000893884 0247_ $$2Handle$$a2128/28735
000893884 0247_ $$2altmetric$$aaltmetric:105091596
000893884 0247_ $$2pmid$$apmid:33931857
000893884 0247_ $$2WOS$$aWOS:000646154400001
000893884 037__ $$aFZJ-2021-02896
000893884 082__ $$a610
000893884 1001_ $$0P:(DE-HGF)0$$aTaher, Ali T.$$b0$$eCorresponding author
000893884 245__ $$aHaematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non‐transfusion‐dependent β‐thalassaemia
000893884 260__ $$aOxford [u.a.]$$bWiley-Blackwell$$c2021
000893884 3367_ $$2DRIVER$$aarticle
000893884 3367_ $$2DataCite$$aOutput Types/Journal article
000893884 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1633443945_22690
000893884 3367_ $$2BibTeX$$aARTICLE
000893884 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000893884 3367_ $$00$$2EndNote$$aJournal Article
000893884 520__ $$aBitopertin is a small molecule selective inhibitor of glycine transporter 1 (GlyT1), initially developed to increase brain extracellular levels of glycine in the vicinity of neuronal N-methyl-D-aspartate receptors for the treatment of schizophrenia. GlyT1, the pharmacological target of bitopertin, is also present as a transmembrane transporter in erythroid cells1 and accounts for 50–55% of glycine uptake in human red blood cells (RBCs).2, 3 Erythroid GlyT1 inhibition by bitopertin leads to reduced intracellular glycine availability, interfering with the first step of haem synthesis, in which 5-aminolevulinate synthase catalyses the condensation reaction between glycine and succinyl-coenzyme A, forming 5-aminolevulinic acid.1
000893884 536__ $$0G:(DE-HGF)POF4-5252$$a5252 - Brain Dysfunction and Plasticity (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000893884 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000893884 7001_ $$aViprakasit, Vip$$b1
000893884 7001_ $$00000-0001-8676-6864$$aCappellini, Maria Domenica$$b2
000893884 7001_ $$0P:(DE-HGF)0$$aKraus, Dominik$$b3
000893884 7001_ $$0P:(DE-HGF)0$$aCech, Patrick$$b4
000893884 7001_ $$0P:(DE-HGF)0$$aVolz, Dietmar$$b5
000893884 7001_ $$0P:(DE-HGF)0$$aWinter, Erica$$b6
000893884 7001_ $$0P:(DE-HGF)0$$aNave, Stephane$$b7
000893884 7001_ $$0P:(DE-Juel1)177772$$aDukart, Juergen$$b8
000893884 7001_ $$0P:(DE-HGF)0$$aKhwaja, Omar$$b9
000893884 7001_ $$0P:(DE-HGF)0$$aKoerner, Annette$$b10
000893884 7001_ $$0P:(DE-HGF)0$$aHermosilla, Ricardo$$b11
000893884 7001_ $$00000-0001-8192-8713$$aBrugnara, Carlo$$b12
000893884 773__ $$0PERI:(DE-600)1475751-5$$a10.1111/bjh.17479$$gp. bjh.17479$$n2$$p474–481$$tBritish journal of haematology$$v194$$x1365-2141$$y2021
000893884 8564_ $$uhttps://juser.fz-juelich.de/record/893884/files/bjh.17479-2.pdf
000893884 8564_ $$uhttps://juser.fz-juelich.de/record/893884/files/DV-BIT74876_Bito_Thal_Letter%20to%20editor_12March2021_JD.pdf$$yPublished on 2021-04-30. Available in OpenAccess from 2022-04-30.
000893884 909CO $$ooai:juser.fz-juelich.de:893884$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000893884 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$aExternal Institute$$b3$$kExtern
000893884 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177772$$aForschungszentrum Jülich$$b8$$kFZJ
000893884 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5252$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000893884 9141_ $$y2021
000893884 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-28
000893884 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-28
000893884 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-28
000893884 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-28
000893884 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-28
000893884 915__ $$0StatID:(DE-HGF)0530$$2StatID$$aEmbargoed OpenAccess
000893884 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRIT J HAEMATOL : 2019$$d2021-01-28
000893884 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-01-28$$wger
000893884 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-01-28
000893884 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000893884 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-28
000893884 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-28
000893884 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBRIT J HAEMATOL : 2019$$d2021-01-28
000893884 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000893884 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-28
000893884 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-28
000893884 920__ $$lyes
000893884 9201_ $$0I:(DE-Juel1)INM-7-20090406$$kINM-7$$lGehirn & Verhalten$$x0
000893884 980__ $$ajournal
000893884 980__ $$aVDB
000893884 980__ $$aUNRESTRICTED
000893884 980__ $$aI:(DE-Juel1)INM-7-20090406
000893884 9801_ $$aFullTexts